These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 11061507

  • 21. The effect of recombinant human TSH on 123I thyroid uptake after intravenous iodide contrast agent.
    Resende M, Corbo R, Vaisman M.
    Nucl Med Commun; 2010 Apr; 31(4):315-9. PubMed ID: 20087238
    [Abstract] [Full Text] [Related]

  • 22. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
    Romão R, Rubio IG, Tomimori EK, Camargo RY, Knobel M, Medeiros-Neto G.
    Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
    [Abstract] [Full Text] [Related]

  • 23. Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects.
    Ramirez L, Braverman LE, White B, Emerson CH.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2836-9. PubMed ID: 9284706
    [Abstract] [Full Text] [Related]

  • 24. Recombinant human thyrotropin stimulation prior to 131I therapy in toxic multinodular goitre with low radioactive iodine uptake.
    Azorín Belda MJ, Martínez Caballero A, Figueroa Ardila GC, Martínez Ramírez M, Gómez Jaramillo CA, Dolado Ardit JI, Verdú Rico J.
    Rev Esp Med Nucl Imagen Mol; 2017 Sep; 36(1):7-12. PubMed ID: 27422154
    [Abstract] [Full Text] [Related]

  • 25. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [Abstract] [Full Text] [Related]

  • 26. Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial.
    Nielsen VE, Bonnema SJ, Hegedüs L.
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1317-22. PubMed ID: 16434453
    [Abstract] [Full Text] [Related]

  • 27. Significance of radioiodine uptake at 72 hours versus 24 hours after pretreatment with recombinant human thyrotropin for enhancement of radioiodine therapy in patients with symptomatic nontoxic or toxic multinodular goiter.
    Duick DS, Baskin HJ.
    Endocr Pract; 2004 Apr; 10(3):253-60. PubMed ID: 15310544
    [Abstract] [Full Text] [Related]

  • 28. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine.
    Albino CC, Mesa CO, Olandoski M, Ueda CE, Woellner LC, Goedert CA, Souza AM, Graf H.
    J Clin Endocrinol Metab; 2005 May; 90(5):2775-80. PubMed ID: 15713700
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Defective thyroidal iodine concentration in protein-calorie malnutrition.
    Gaitan JE, Mayoral LG, Gaitan E.
    J Clin Endocrinol Metab; 1983 Aug; 57(2):327-33. PubMed ID: 6408112
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [The use for recombinant human TSH in patients with toxic and non-toxic nodular goiter].
    Jedrzejuk D, Milewicz A.
    Postepy Hig Med Dosw (Online); 2005 May 13; 59():188-92. PubMed ID: 15928602
    [Abstract] [Full Text] [Related]

  • 36. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters.
    Huysmans AK, Hermus RM, Edelbroek MA, Tjabbes T, Oostdijk, Ross HA, Corstens FH, Kloppenborg PW.
    Thyroid; 1997 Aug 13; 7(4):535-9. PubMed ID: 9292939
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
    Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A.
    J Clin Endocrinol Metab; 2002 Sep 13; 87(9):4063-8. PubMed ID: 12213846
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.